CTOs on the Move


 
Taaneh is engaged in commercializing the use of diamond particles, an inert material, for the authentication, identification and construction of anti-counterfeiting systems. The technology has applications in diverse sectors including the pharmaceutical industry, cosmetics and fragrances, foods, textiles, paint, ink, currency, mechanical components, electronics, and packaging. Taaneh`s IP and patent positions are designed to protect the technology that is the basis for the company`s business plan.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.taaneh.com
  • 304 Wall Street
    Princeton, NJ USA 08540
  • Phone: 609.879.2377

Executives

Name Title Contact Details

Similar Companies

OMEGA ALPHA PHARMACEUTICALS

OMEGA ALPHA PHARMACEUTICALS INC. is a Scarborough, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celera Corporation

Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a

Marker Therapeutics

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStartâ„¢ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

Paragon28

Paragon 28 was established for unmet needs of the foot and ankle community. Dedicated to creating solutions to improve the treatment of foot and ankle conditions.